PYXS stock forecast, quote, news & analysis
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma... Show more
Why Pyxis Oncology (PYXS) Stock Is Down -36.6% in the Last 30 Days
Key Takeaways
- PYXS shares fell roughly 36.6% over the trailing 30 days, sliding from about $2.90 to $1.84 as a dilutive equity offering reset the stock's valuation.
- The decline was driven primarily by a registered public offering priced at $2.90 per share that closed on October 1, 2026, raising approximately $110 million in upfront gross proceeds.
- The financing, which could total up to $282.6 million if milestone-linked warrants are exercised, diluted existing shareholders and underscored the company's ongoing capital needs.
- Over the quarter, the stock was highly volatile, climbing toward $4.15 in early September before reversing sharply to close near $1.84.
- Pyxis's investment case remains tied to MICVO, its lead antibody-drug conjugate in Phase 1 testing for head and neck cancer, with updated data anticipated in the second half of 2026.
- For deeper context on valuation, financials, and expectations, explore Pyxis Oncology's Price Targets, Earnings, and Forecast pages.
- See how AI-driven trading strategies approach this and other tickers in Trending AI Robots.
Pyxis Oncology (PYXS) Company Overview and Market Position
Pyxis Oncology, Inc. (Nasdaq: PYXS) is a clinical-stage biopharmaceutical company developing next-generation therapies for difficult-to-treat cancers. Its lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a structural component of the tumor extracellular matrix that is selectively overexpressed in solid tumors and largely absent from normal adult tissue.
MICVO is being evaluated as a monotherapy in a Phase 1 study for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a Phase 1/2 study. The candidate has received Fast Track Designation from the U.S. Food and Drug Administration, and the company has reported positive preliminary monotherapy data. As a pre-revenue developer, Pyxis relies on equity financing to fund its pipeline, which makes capital raises and clinical catalysts central to how investors value the stock.
Pyxis Oncology (PYXS) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, PYXS declined from a closing price of $2.90 to approximately $1.84, a drop of about 36.6%. The selloff was sharp and concentrated: after trading near $2.90 in late September, the stock gapped lower on heavy volume as the equity offering was priced, then continued drifting downward through much of October before stabilizing in the high-$1.60s to low-$1.80s range.
The quarterly picture is similarly downbeat on a net basis, with shares falling roughly 36.8% from about $2.91 at the end of July. That headline figure, however, masks significant intra-quarter volatility. The stock rallied through August and into early September, reaching an intraday peak near $4.15, before the financing announcement triggered a reversal that erased those gains.
What Drove PYXS Stock Price in the Last 30 Days
The dominant catalyst was a registered public offering that closed on October 1, 2026. The company sold 36,047,919 shares of common stock at $2.90 per share, alongside pre-funded warrants, and issued common warrants covering roughly 49.3 million additional shares. The offering generated approximately $110 million in upfront gross proceeds and could deliver up to $282.6 million in total if the warrants are exercised.
The pricing of roughly 36 million new shares at $2.90—well below the stock's early-September highs—diluted existing shareholders and signaled that the company needed additional capital to advance MICVO toward a planned Phase 3 "Headliner" trial in second-line-plus R/M HNSCC. The milestone-linked warrants carry an exercise price of $3.50 and are tied to the company's disclosure of overall survival data from the Phase 1 monotherapy study, expected in the first half of 2027. Participation from institutions including OrbiMed, GordonMD Global Investments, BVF Partners, Coastlands Capital, and RTW Investments validated the science but did not offset the near-term dilution pressure.
What Drove PYXS Stock Performance Over the Last Quarter
The broader quarterly trend reflects a clinical-stage biotech caught between positive momentum and persistent funding requirements. In July, Pyxis completed a private placement that raised approximately $50 million upfront, extending its cash runway into the second quarter of 2027. Enthusiasm around the MICVO program, including positive preliminary data in R/M HNSCC and a series of investor conference appearances in September, helped lift shares toward $4.15.
That momentum reversed once the company pursued an additional, larger public offering, underscoring the reality that advancing an oncology pipeline through late-stage trials is capital-intensive. Leadership changes—Thomas Civik was appointed chief executive officer effective September 4, 2026—and ongoing net losses also contributed to a cautious tone. For the second quarter of 2026, Pyxis reported a net loss of $25.3 million, or $0.40 per share.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots from a platform that operates hundreds of automated strategies across thousands of tickers. Rather than listing every available bot, the section highlights only the top-performing and most relevant strategies, giving traders a focused view of where AI-driven activity is concentrated. The bots vary widely in their approach, holding periods, and performance metrics, so they can suit different market conditions and risk preferences. For investors following volatile names such as Pyxis Oncology, exploring these automated strategies can offer an additional, data-driven perspective on timing and positioning.
PYXS Stock Forecast Drivers: What Investors Should Watch Next
The near-term story for PYXS will hinge on clinical execution and upcoming data disclosures. The company expects to report updated MICVO Phase 1 monotherapy data in R/M HNSCC in the second half of 2026, followed by updated Phase 1/2 combination data with KEYTRUDA in the fourth quarter of 2026. Overall survival data tied to the milestone-linked warrants is anticipated in the first half of 2027.
Investors should also monitor the company's cash position and any additional financing activity, the progress of the planned Phase 3 Headliner trial, FDA interactions and regulatory milestones, and analyst expectations for the stock. As a pre-revenue developer with a single lead asset, Pyxis remains highly sensitive to clinical results, dilution risk, and shifts in biotech sector sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PYXS sees its Stochastic Oscillator climbs out of oversold territory
On November 09, 2026, the Stochastic Oscillator for PYXS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 65 instances where the indicator left the oversold zone. In 58 of the 65 cases the stock moved higher in the following days. This puts the odds of a move higher at over 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PYXS's RSI Oscillator exited the oversold zone, 30 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for PYXS just turned positive on October 23, 2026. Looking at past instances where PYXS's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.
Following a +5.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where PYXS advanced for three days, in 214 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PYXS as a result. In 70 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PYXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PYXS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.103) is normal, around the industry mean (3.498). P/E Ratio (-1.186) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (19.120) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. PYXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PYXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology